Telemedicine Program in Type 1 Diabetes and CSII

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Randomized Crossover Clinical Trial in Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion to Assess the Impact of Telemedicine vs. Conventional Medical Care. Integral Clinical Impact and Cost

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02790645
• Other study ID #: CSII TELEMEDICINE PROGRAM
• Status: Completed
• Phase: N/A
• First received: February 9, 2016
• Last updated: July 12, 2017
• Start date: September 2012
• Est. completion date: September 19, 2016

Study information

• Verified date: February 2016
• Source: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diabetes mellitus is a chronic disease of high socio-health relevance for their clinical and economic implications (risk of complications, disability ...) (healthcare costs). Strict glycemic control and intensive treatment and support have shown long-term patient with type 1 diabetes mellitus (DM1) improved health. The intensive insulin therapy involves the administration of insulin through 3 or more injections per day (MDI), or through a continuous subcutaneous insulin infusion (CSII). New technologies applied to the treatment of DM1, such as telemedicine, could bring benefits to patients. The available scientific evidence to date shows that telemedicine systems have beneficial or neutral effects on glycemic control, expressed in terms of HbA1c in patients with type 1 diabetes treated with MDI or CSII. They have also shown not to worsen the quality of life and reduce the costs associated with the care of these subjects. However, studies published to date are generally short follow-up, small sample size, and have not evaluated other biological parameters such as glycemic variability, inflammatory markers and markers of oxidative stress as well as a psychological assessment including depression, anxiety, Diabetes-related distress and fear of hypoglycemia. It has been designed a randomized crossover 18 months in order to study the effect of a telemedicine program in a group of subjects with DM1 in CSII on clinical variables of metabolic control variables, including parameters of glycemic variability, markers of inflammation and oxidative stress, psychological variables and quality of life, and associated costs.

Description:

Randomized crossover clinical trial about the impact of a telemedicine program (Emminens Conecta® System, Roche Diagnostics SL) vs. the conventional medical follow-face of 18 months for the care of patients with DM1 intensive treatment with CSII (Accu-Chek Spirit®, Roche SL).

Two groups: one group with interactive clinical monitoring through a telemedicine platform (TM) and other conventional medical follow-up group (SMC) during 6 months. Being a crossover trial, both groups passing through both conditions (TM and SMC) during 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: September 19, 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 85 Years

Eligibility

Inclusion Criteria:

• Type 1 diabetes over 2 years of development with C plasma levels <0.5 ng / ml, and ISCI treated for> 6 months peptide.

• Age between 16 and 65 years (inclusive).

• HbA1c <10%.

• Absence of concomitant drug therapy that could affect blood glucose levels.

• Absence of chronic renal failure, abnormal liver function tests, thyroid disease active (except properly replaced hypothyroidism).

• Absence of acute decompensation Ketotic at baseline.

Exclusion Criteria:

• type 2 diabetes.

• type 1 diabetes treated with multiple daily insulin injections.

• Women pregnant or planning pregnancy.

• severe macrovascular or microvascular complications

• disabling psychological disorders.

• No collaboration (not signed informed consent).

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Other:
• Group 2a. Telemedicine program
CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
• Group 1a. Control
Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
• Group 1b.Telemedicine program
After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
• Group 2b. Control
After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	Andaluz Health Service, Ministerio de Economía y Competitividad, Spain, Roche Pharma AG

References & Publications (2)

Blanchet KD. Telehealth and diabetes monitoring. Telemed J E Health. 2008 Oct;14(8):744-6. doi: 10.1089/tmj.2008.8483. — View Citation

Jansà M, Vidal M, Viaplana J, Levy I, Conget I, Gomis R, Esmatjes E. Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control. Diabetes Res Clin Pract. 2006 Oct;74(1):26-32. Epub 2006 Apr 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).		Baseline: Group 1 and 2
Primary	Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of inflammatory markers (hs-CRP).		Baseline: Group 1 and 2
Secondary	Assessment of inflammatory markers (IL-6).		Baseline: Group 1 and 2
Secondary	Assessment of inflammatory markers (TNF-a).		Baseline: Group 1 and 2
Secondary	Assessment of inflammatory markers (MCP-1).		Baseline: Group 1 and 2
Secondary	Assessment of inflammatory markers (hs-CRP).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of inflammatory markers (IL-6).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of inflammatory markers (TNF-a).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of inflammatory markers (MCP-1).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of redox markers (CAT).		Baseline: Group 1 and 2
Secondary	Assessment of redox markers (TBARS).		Baseline: Group 1 and 2
Secondary	Assessment of redox markers (oxidized LDL).		Baseline: Group 1 and 2
Secondary	Assessment of redox markers (CAT).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of redox markers (TBARS).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of redox markers (oxidized LDL).		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of quality of life with the DQOL		Baseline: Group 1 and 2
Secondary	Assessment of quality of life with the DQOL		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of depression with the BDI-II		Baseline: Group 1 and 2
Secondary	Assessment of depression with the BDI-II		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of anxiety with the STAI		Baseline: Group 1 and 2
Secondary	Assessment of anxiety with the STAI		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of distress related to diabetes with the DDS		Baseline: Group 1 and 2
Secondary	Assessment of distress related to diabetes with the DDS		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of treatment satisfaction with the DTSQ		Baseline: Group 1 and 2
Secondary	Assessment of treatment satisfaction with the DTSQ		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of fear of hypoglycemia with the FH-15		Baseline: Group 1 and 2
Secondary	Assessment of fear of hypoglycemia with the FH-15		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.		Baseline: Group 1 and 2; 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary	Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.		6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)